Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6094330 | Gastroenterology | 2014 | 12 Pages |
Abstract
CD44+ cells isolated from human HCC tissues and cell lines have CSC activities in vitro and form a larger number of xenograft tumors in mice than CD44- cells. TAMs produce IL6, which promotes expansion of these CSCs and tumorigenesis. Levels of IL6 in human HCC samples correlate with tumor stage and markers of CSCs. Blockade of IL6 signaling with tocilizumab, a drug approved by the Food and Drug Administration for treatment of rheumatoid arthritis, inhibits TAM-stimulated activity of CD44+ cells. This drug might be used to treat patients with HCC.
Keywords
CSCFDAEpCAMshRNANSGHCCsmall hairpin RNASTATepithelial mesenchymal transitioninterleukinTAMEMTIntraperitoneallyCancer biologyFood and Drug AdministrationLiver cancercancer stem cellTumor-associated macrophageSignal transducer and activator of transcriptionMouse modelepithelial cell adhesion moleculeHepatocellular carcinoma
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Shanshan Wan, Ende Zhao, Ilona Kryczek, Linda Vatan, Anna Sadovskaya, Gregory Ludema, Diane M. Simeone, Weiping Zou, Theodore H. Welling,